Literature DB >> 21114391

Psychological distress as a negative survival factor for patients with hematologic malignancies who underwent allogeneic hematopoietic stem cell transplantation.

Ji Eun Park1, Kyung Im Kim, Sung Soo Yoon, Bong Jin Hahm, Sang Min Lee, Jeong Hyun Yoon, Wan Gyoon Shin, Hye Suk Lee, Jung Mi Oh.   

Abstract

STUDY
OBJECTIVE: To evaluate the influence of distress on overall survival of patients with hematologic malignancies who underwent allogeneic stem cell transplantation (allo-SCT) and to analyze the possible risk factors for death.
DESIGN: Retrospective cohort study.
SETTING: Large tertiary care teaching hospital. PATIENTS: Seventy-seven patients (aged ≥ 15 yrs) with hematologic malignancies who underwent allo-SCT between January 2000 and August 2007; 20 patients with distress history were matched in a 1:3 ratio with 57 patients without distress history.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was overall survival, defined as the time from allo-SCT to disease-related death or last date of follow-up. Secondary outcomes were time to hematologic recovery (absolute neutrophil count ≥ 500 cells/mm³) from day of allo-SCT, length of hospital stay, and opioid usage. Sociodemographic information and clinical characteristics were analyzed for possible risk factors. Patient history of psychological distress resulted in a significantly higher mortality rate in the first year after allo-SCT (hazard ratio [HR] 3.05, 95% confidence interval [CI] 1.48-6.28, p=0.001) and led to a shorter overall survival rate (HR 1.63, 95% CI 0.86-3.10, p=0.133). However, psychological distress had no effect on hospital length of stay, hematologic recovery time, opioid usage status, or dose of opioid analgesics used. Factors associated with death after allo-SCT in the univariate analysis (p<0.05) were high-relapse risk disease, umbilical cord blood SCT, total-body irradiation-containing conditioning regimen, and higher educational background. In the multivariate analysis, high relapse risk (HR 3.85, 95% CI 1.81-8.20, p<0.001) and total-body irradiation-containing conditioning regimen (HR 3.50, 95% CI 1.29-9.51, p=0.01) were identified as risk factors for death.
CONCLUSION: A history of psychological distress before allo-SCT, after adjusting for other patient- and disease-related prognostic factors, had a significant influence on early death in the first year after transplantation.

Entities:  

Mesh:

Year:  2010        PMID: 21114391     DOI: 10.1592/phco.30.12.1239

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  4 in total

1.  High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age.

Authors:  J Hefner; M Kapp; K Drebinger; A Dannenmann; H Einsele; G-U Grigoleit; H Faller; H Csef; S Mielke
Journal:  Bone Marrow Transplant       Date:  2014-01-20       Impact factor: 5.483

2.  Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.

Authors:  Daniel R Richardson; Ying Huang; Heather L McGinty; Patrick Elder; Joanna Newlin; Cyndi Kirkendall; Leslie Andritsos; Don Benson; William Blum; Yvonne Efebera; Sam Penza; Craig Hofmeister; Samantha Jaglowski; Rebecca Klisovic; Sumithira Vasu; Basem William; Steven Devine; Ashley E Rosko
Journal:  Bone Marrow Transplant       Date:  2018-02-14       Impact factor: 5.483

3.  Psychosocial factors predicting survival after allogeneic stem cell transplant.

Authors:  Brindha Pillay; Stuart J Lee; Lynda Katona; Sue Burney; Sharon Avery
Journal:  Support Care Cancer       Date:  2014-04-16       Impact factor: 3.603

4.  A systematic review of the risk factors for clinical response to opioids for all-age patients with cancer-related pain and presentation of the paediatric STOP pain study.

Authors:  Ersilia Lucenteforte; Laura Vagnoli; Alessandra Pugi; Giada Crescioli; Niccolò Lombardi; Roberto Bonaiuti; Maurizio Aricò; Sabrina Giglio; Andrea Messeri; Alessandro Mugelli; Alfredo Vannacci; Valentina Maggini
Journal:  BMC Cancer       Date:  2018-05-18       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.